You are in: eMedicine Specialties > Medicine, Ob/Gyn, Psychiatry, and Surgery > Infectious Diseases
|
Bacteroides Infection Last Updated: December 15, 2006 |
|
| Synonyms and related keywords: anaerobic gram-negative bacilli, AGNB, Bacteroides fragilis, B fragilis, Prevotella species, Porphymonas species, Bacteroides distasonis, B distasonis, Bacteroides ovatus, B ovatus, Bacteroides thetaiotaomicron, B thetaiotaomicron, Bacteroides vulgatus, B vulgatus, Prevotella melaninogenica, P melaninogenica, Prevotella intermedia, P intermedia, Porphyromonas asaccharolytica, P asaccharolytica, Prevotella oralis, P oralis, Prevotella oris, P oris, Prevotella bivia, P bivia, Bacteroides bivia, B bivia, Prevotella disiens, P disiens, Bacteroides disiens, Bacteroides melaninogenicus group, B melaninogenicus group, perirectal abscess, decubitus ulcer, bedsore, bed sore, pressure sore, intra-abdominal abscess, intraabdominal abscess, aspiration pneumonia, lung abscess, chronic otitis media, chronic sinusitis, oral cavity abscess, abscesses around the oral cavity, human bites, paronychia, brain
abscesses, osteomyelitis, Bacteroidaceae
|
|   |
AUTHOR INFORMATION
| Section 1 of 9  |
|
| Author: Itzhak Brook, MD, MSc, Professor, Department of Pediatrics, Georgetown University School of Medicine |
| Itzhak Brook, MD, MSc, is a member of the following medical societies:
American College of Physicians-American Society of Internal Medicine,
American Federation for Medical Research,
American Medical Association,
Anaerobe Society of the Americas,
Association for Professionals in Infection Control and Epidemiology,
Association of Military Surgeons of the US,
Infectious Diseases Society of America,
International Immunocompromised Host Society,
International Society for Infectious Diseases,
Medical Society of the District of Columbia,
New York Academy of Sciences,
Pediatric Infectious Disease Society,
Society for Ear, Nose and Throat Advances in Children,
Society for Experimental Biology and Medicine,
Society for Pediatric Research,
Southern Medical Association, and
Surgical Infection Society |
| Editor(s): Jeffrey D Band, MD, Clinical Professor of Medicine, Wayne State University School of Medicine; Director, Division of Infectious Diseases and International Medicine, William Beaumont Hospital Corporation; Francisco Talavera, PharmD, PhD, Senior Pharmacy Editor, eMedicine;
Ronald A Greenfield, MD, Professor, Chief, Department of Internal Medicine, Section of Infectious Disease, University of Oklahoma College of Medicine;
Eleftherios Mylonakis, MD, PhD, Assistant Professor of Medicine, Harvard Medical School, Assistant in Medicine, Division of Infectious Disease, Massachusetts General Hospital;
and Burke A Cunha, MD, MACP, Professor of Medicine, State University of New York School of Medicine at Stony Brook; Chief, Infectious Disease Division, Winthrop-University Hospital |
Disclosure
|   |
INTRODUCTION
| Section 2 of 9  |
|
Background: This monograph describes infections caused by the Bacteroides fragilis group and other anaerobic gram-negative bacilli (AGNB) that were previously included in the Bacteroides species but are now included in the Prevotella and Porphymonas species. Infections due to AGNB are common, yet the specific identification of AGNB in these infections is difficult.
Bacteroides species are anaerobic bacteria that are predominant components of the bacterial florae of mucous membranes and, therefore, are a common cause of endogenous infections. Bacteroides infections can occur in all body sites, including the CNS, the head, the neck, the chest, the abdomen, the pelvis, the skin, and the soft tissues.
Inadequate therapy against these anaerobic bacteria may lead to clinical failures. Because of their fastidiousness, they are difficult to isolate and are often overlooked. Their isolation requires appropriate methods of collection, transportation, and cultivation of specimens. Treatment is complicated by 3 factors: slow growth, increasingly encountered resistance to antimicrobials, and the polymicrobial nature of the infection.
The B fragilis group, a member of the Bacteroidaceae family, includes B fragilis (occurs with the greatest frequency in clinical infections), Bacteroides distasonis, Bacteroides ovatus, Bacteroides thetaiotaomicron, and Bacteroides vulgatus. These bacteria are resistant to penicillins, mostly through the production of beta-lactamase. They are part of the normal GI florae and predominate in intra-abdominal infections and infections originating from those florae (eg, perirectal abscesses, decubitus ulcers). Enterotoxigenic B fragilis (ETBF) are also a potential cause of diarrhea.
Pigmented Prevotella, such as Prevotella melaninogenica and Prevotella intermedia (which were previously called the Bacteroides melaninogenicus group), Porphyromonas (eg, Porphyromonas asaccharolytica), and nonpigmented Prevotella (eg, Prevotella oralis, Prevotella oris) are part of the normal oral and vaginal florae and are the predominant AGNB isolated from respiratory tract infections and their complications, including aspiration pneumonia, lung abscess, chronic otitis media, chronic sinusitis, abscesses around the oral cavity, human bites, paronychia, brain abscesses, and osteomyelitis. Prevotella bivia and Prevotella disiens (previously called Bacteroides) are important in obstetric and gynecologic infections. Pathophysiology: Most infections due to AGNB originate from the endogenous mucosal membrane florae. Knowledge of the common mode of distribution allows for a logical choice of antimicrobial therapy for infections in these sites.
AGNB infections are generally polymicrobial. The number of isolates can reach 5-10 organisms. The type of copathogens depends on the infection site and the circumstances of the infection. Antimicrobial therapy should be directed at all major aerobic and anaerobic pathogens. AGNB promote infection through synergy with their aerobic and anaerobic counterparts and with each other.
An indirect pathogenic role of AGNB is their ability to produce the enzyme beta-lactamase, which allows them to protect themselves and other penicillin-susceptible organisms from the activity of penicillins. Frequency:
- In the US: The exact frequency of AGNB infection is difficult to calculate because of inappropriate methods of collection, transportation, and cultivation of specimens. AGNB are more commonly found in chronic infections. Their rate of recovery in blood cultures is 2-5% and is higher in association with patients who have predisposing conditions.
- Internationally: The frequency of these infections appears to be higher in developing countries, where therapy is often inadequate or delayed.
Mortality/Morbidity: The mortality rate has decreased over the past 3 decades because of early recognition and initiation of proper prophylactic and therapeutic antimicrobial therapies.
Age: AGNB infections can occur in patients of all ages; however, the frequency of head and neck infections is higher in pediatric patients than in other patients.
|   |
CLINICAL
| Section 3 of 9  |
|
History: AGNB infections occur more often in chronic infections and in association with the predisposing conditions discussed below. However, they can also cause acute infections (ie, maxillary sinusitis associated with dental infections, intra-abdominal infections following perforation). - AGNB can cause a variety of intracranial infections, including brain abscess, subdural empyema, epidural abscess, and meningitis (usually from contiguous spread from adjacent foci of infection). Brain abscesses are commonly caused by chronic infections in the ears, the mastoids, the sinuses, the oropharynx, the teeth, or the lungs.
- Hematogenous spread can occur after dental, oropharyngeal, pulmonary, or intra-abdominal infection. Rarely, bacteremia of another origin or endocarditis can lead to such infection.
- Head and neck infections: Anaerobes, including AGNB, are recovered from a variety of infections, especially in their chronic form. Head and neck infections include chronic otitis media; sinusitis; mastoiditis; tonsillar, peritonsillar, and retropharyngeal abscesses; cervical lymphadenitis; all deep neck space infections; thyroiditis; odontogenic infections; and postsurgical and nonsurgical head and neck wounds and abscesses.
- Sinusitis is complicated by anaerobes, including AGNB, when it turns chronic and oxygen levels decline. Anaerobes are isolated from 10% of patients with acute maxillary sinusitis (mostly secondary to odontogenic infection), but they are found in as many as 67% of chronic infections of the maxillary, ethmoid, frontal, and sphenoid sinuses. The infection may spread via anastomosing veins or contiguously to the CNS. Complications include orbital cellulitis, meningitis, cavernous sinus thrombosis, and epidural and subdural brain abscesses.
- Tonsillitis, whether acute or chronic, may have AGNB involvement. AGNB can also be involved with tonsillitis complications, including internal jugular vein thrombophlebitis, which often causes postanginal sepsis. Prevotella species and other anaerobes are recovered from tonsillar or retropharyngeal abscesses without any aerobic bacteria, and they are isolated in cases of Vincent angina.
- Pleuropulmonary infections: Aspiration of oropharyngeal or gastric secretions and periodontal or gingival disease are risk factors for developing anaerobic pleuropulmonary infection due to AGNB and to other anaerobes. The infection can progress from pneumonitis to necrotizing pneumonia and lung abscess, with or without empyema.
- Intra-abdominal infections
- Secondary peritonitis and abdominal abscesses generally occur after entry of enteric organisms into the peritoneal cavity through perforation of the intestine or other viscus as a result of obstruction, infarction, or trauma.
- The more distal the perforation, the more numerous the types and number of organisms that gain access into the peritoneal cavity (ie, perforations in the descending colon are associated with spillage of more organisms than perforations in proximal parts of the colon).
- Enterotoxigenic B fragilis are considered an emerging enteropathogen-causing diarrhea.
- Female genital tract infection: These infections include bacterial vaginosis; soft tissue perineal, vulvar, and Bartholin gland abscesses; endometritis; pyometra; salpingitis; tubo-ovarian abscesses; adnexal abscess; pelvic inflammatory disease, which may include pelvic cellulitis and abscess; amnionitis; septic pelvic thrombophlebitis; intrauterine device–associated infection; septic abortion; and postsurgical obstetric and gynecologic infections.
- Skin and soft tissue infections
- Infections involving AGNB include superficial infections, such as infected cutaneous ulcers, cellulitis, secondary diaper rash, gastrostomy or tracheostomy site wounds, infected subcutaneous sebaceous or inclusion cysts, eczema, scabies or kerion infections, paronychia, hidradenitis suppurativa, and pyoderma.
- Subcutaneous tissue infections and postsurgical wound infections that may also involve the skin include cutaneous and subcutaneous abscesses, decubitus ulcers, infected diabetic (vascular or trophic) ulcers, breast abscesses, bite wounds, anaerobic cellulitis and gas gangrene, bacterial synergistic gangrene, infected pilonidal cyst or sinus, Meleney ulcer, and burn wound infection.
- Deeper anaerobic soft tissue infections are necrotizing fasciitis, necrotizing synergistic cellulitis, gas gangrene, and crepitus cellulitis. These infections can involve only the fascia and/or the muscle surrounded by the fascia, inducing myositis and myonecrosis.
- Anaerobic infections, such as decubitus ulcers or diabetic foot ulcers, are generally polymicrobial and are often complicated by osteomyelitis or bacteremia.
- Deep tissue infections, such as necrotizing cellulitis, fasciitis, and myositis, often involve clostridial organisms and Staphylococcus pyogenes. They may be polymicrobic; may contain gas and gray, thin, putrid pus; and are associated with bacteremia and mortality.
- Osteomyelitis and septic arthritis: Osteomyelitis in the long bones and the cranial and facial bones is frequently polymicrobic and may be associated with anaerobes in patients with peripheral vascular disease and decubitus ulcers.
- Bacteremia
- The prevalence of anaerobes, including AGNB, in bacteremia was 5-15%. However, rates have declined in the last decade to 2-6%. Which organisms are involved depends on their portal of entry and the underlying disease. The common isolates are the B fragilis group (60-75% of isolates).
- The B fragilis group and clostridial organisms are associated with a GI source.
- Pigmented Prevotella, Porphyromonas, and Fusobacterium are associated with the oropharynx and a pulmonary source.
- Fusobacterium species involve the female genital tract.
- Propionibacterium acnes is associated with a foreign body.
- Peptostreptococcus species are associated with all sources but especially with oropharyngeal, pulmonary, and female genital tract sources.
- Predisposing factors include neoplasms; hematologic disorders; organ transplantation; intestinal obstruction; decubitus ulcers; dental extraction; diabetes mellitus; postsplenectomy; use of cytotoxic agents or corticosteroids; total body irradiation; and recent GI, obstetric, or gynecologic surgery.
- Features typical of bacteremia due to anaerobes include metastatic lesions, hyperbilirubinemia, and suppurative thrombophlebitis.
- The mortality rate is 15-30% and improves with early appropriate antimicrobial therapy and resolution of the primary infection.
Causes: - Conditions predisposing patients to AGNB infections include the exposure of sterile sites to a high inoculum of indigenous mucous membrane florae; use of antibiotics that are ineffective against AGNB; reduced blood supply; and tissue necrosis, which lowers the oxidation-reduction potential and favors the growth of anaerobes. Conditions that lower the blood supply include trauma, foreign body, malignancy, surgery, edema, shock, colitis, and vascular disease.
- Infection with aerobic bacteria can make the local tissue conditions more favorable for the growth of anaerobes. The host defenses can become impaired by anaerobic conditions and anaerobic bacteria.
- Anaerobic infection is often manifested by suppuration, thrombophlebitis, abscess formation, and gangrenous destruction of tissue associated with gas.
- Anaerobes, including AGNB, are common in chronic infections. Therapy with antimicrobials, such as aminoglycosides, trimethoprim-sulfamethazine, and older quinolones, often does not eradicate anaerobes.
- Certain infections that often involve anaerobes include brain abscess, oral or dental infections, human or animal bites, aspiration pneumonia, lung abscesses, amnionitis, endometritis, septic abortions, pelvic inflammatory disease, tubo-ovarian abscess, peritonitis following viscus perforation, abscesses in and around the oral and rectal areas, and pus-forming necrotizing infections of soft tissue or muscle.
- Some tumors, such as colonic, uterine, and bronchogenic carcinomas and necrotic tumors of the head and the neck, can become infected with anaerobes.
|   |
WORKUP
| Section 4 of 9  |
|
Lab Studies:
- Collection of specimens of anaerobic bacteria is important because documentation of an anaerobic infection is through culture of organisms from the infected site. Appropriate documentation of anaerobic infection requires proper collection of appropriate specimens, expeditious transportation, and careful laboratory processing.
- Specimens must be obtained free of contamination. Inadequate techniques or media can lead to missing the presence of anaerobic bacteria or the assumption that only aerobic organisms are present in a mixed infection.
- Because anaerobes are present on skin and mucous membranes, even minimal contamination with normal florae can be misleading.
- Unacceptable or inappropriate specimens can yield normal florae and, therefore, have no or little diagnostic value.
- Appropriate materials should be obtained by using techniques that bypass the normal florae.
- Direct-needle aspiration is the best method of obtaining a culture; the use of swabs is much less desirable.
- Specimens obtained from normally sterile sites, such as blood or spinal, joint, or peritoneal fluids, are collected after thorough skin decontamination.
- Two approaches are used to culture the maxillary sinus following sterilization of the canine fossa or the nasal vestibule, via either the canine fossa or the inferior meatus.
- Urine is collected by percutaneous suprapubic bladder aspiration.
- Other specimens can be collected from abscess contents, from deep aspirates of wounds, and by special techniques, such as transtracheal aspirates or direct lung puncture.
- Specimens of the lower respiratory tract are difficult to obtain without contamination with indigenous florae. Double-lumen catheter bronchial brushing and bronchoalveolar lavage, cultured quantitatively, can be useful.
- Culdocentesis fluid obtained after decontamination of the vagina is acceptable.
- Transportation of specimens should be prompt unless transport devices are available. Transport devices generally contain oxygen-free environments provided by a mixture of carbon dioxide, hydrogen, and nitrogen, plus an aerobic condition indicator. Specimens should be placed into an anaerobic transporter as soon as possible.
- Liquid or tissue specimens are always preferred to swabs.
- Liquid specimens are inoculated into an anaerobic transport vial or a syringe and a needle.
- All air bubbles are expelled from the syringe. Insertion of the needle tip into a sterile rubber stopper is no longer recommended. Because air gradually diffuses through the plastic syringe wall, specimens should be processed in less than 30 minutes.
- Swabs are placed in sterilized tubes containing carbon dioxide or prereduced anaerobically sterile Carey and Blair semisolid media.
- Tissue specimens can be transported in an anaerobic jar or in a sealed plastic bag rendered anaerobic.
- Gram stain of a smear of the specimen provides important preliminary information regarding the types of organisms present, suggests appropriate initial therapy, and serves as a quality control.
- Cultures should be immediately placed under anaerobic conditions and should be incubated for 48 hours or longer. An additional 36-48 hours is generally required for species- or genus-level identification by using biochemical tests. Kits containing these tests are commercially available.
- A rapid enzymatic test enables identification after only 4 hours of aerobic incubation.
- Gas-liquid chromatography of metabolites is often used.
- Nucleic acid probers and polymerase chain reaction methods are also being developed for rapid identification.
- Detailed procedures of laboratory methods can be found in microbiology manuals.
- Antimicrobial susceptibility testing of AGNB has become less predictable because their resistance to several antimicrobials has increased. Screening of AGNB isolates for beta-lactamase activity may be helpful. However, occasional strains may resist beta-lactam antibiotics through other mechanisms.
- Routine susceptibility testing is time-consuming and often unnecessary. However, testing the susceptibility of isolates recovered from sterile body sites and/or those that are clinically important (ie, blood cultures, bone, CNS, serious infections) and have variable susceptibilities, especially those isolated in pure culture from properly collected specimens, is important.
- Antibiotics that should be tested include penicillin, a broad-spectrum penicillin, a penicillin plus a beta-lactamase inhibitor, clindamycin, chloramphenicol, a second-generation cephalosporin (eg, cefoxitin), newer quinolones, metronidazole, and a carbapenem.
- The recommended methods include agar microbroth and macrobroth dilution.
- Newer methods include the E-test and the spiral gradient end point system.
Imaging Studies:
- Radiologic or imaging studies are helpful. The presence of gas in the infected site is highly suggestive of anaerobic infection.
|
|
|   |
TREATMENT
| Section 5 of 9  |
|
Medical Care: - The patient's recovery from anaerobic infection depends on prompt and proper management according to the following 3 principles:
- Toxins produced by anaerobes must be neutralized.
- The environment must be changed to prevent local bacterial proliferation.
- The spread of bacteria must be limited.
- The environment is controlled by debriding necrotic tissue, draining pus, improving circulation, alleviating obstruction, and increasing tissue oxygenation.
- Certain types of adjunctive therapy, such as hyperbaric oxygen therapy, may be useful but remain unproven.
- In many cases, antimicrobial therapy is the only form of therapy required, but it can also be an adjunct to a surgical approach.
- Because anaerobic bacteria are generally recovered mixed with aerobic organisms, the appropriate choice for antimicrobial agents should provide adequate treatment of both groups of pathogens.
- When choosing antimicrobials for the treatment of mixed infections, consider their aerobic and anaerobic antibacterial spectrum and their availability in oral or parenteral form.
- Some antimicrobials have a limited range of activity. For example, metronidazole is active only against anaerobes and cannot be administered as a single agent in mixed infections. Others, such as imipenem, have wide spectra of activity against aerobes and anaerobes.
- Because culture results are often not available, many patients are treated empirically.
- Antimicrobial resistance patterns may vary. Some anaerobes have become, or may become, resistant to antimicrobials.
- The B fragilis group is almost uniformly susceptible to metronidazole, carbapenems, chloramphenicol, and combinations of a penicillin and beta-lactamase inhibitors. Resistance to other agents varies.
- Aside from susceptibility patterns, other factors influencing the choice of antimicrobials include their pharmacokinetics, their toxicity, their effect on the normal florae, their bactericidal activity, and their ability to penetrate into sites of infection.
- Although identification of organisms and their susceptibility is needed for optimal therapy, often the clinical setting and the Gram stain results from the specimen are helpful.
- Antimicrobials useful in anaerobic infection are as follows:
- Penicillins
- Penicillin G is still the drug of choice against most non–beta-lactamase–producing AGNB. However, in addition to the B fragilis group, which is resistant to penicillin, other AGNB show increased resistance. These include pigmented Prevotella and Porphyromonas species, P bivia, P disiens, Bilophila wadsworthia, and Bacteroides splanchnicus.
- The combination of beta-lactamase inhibitors (eg, clavulanic acid, sulbactam, tazobactam) with a beta-lactam antibiotic (eg, ampicillin, amoxicillin, ticarcillin, piperacillin) can overcome these beta-lactamase–producing AGNB.
- In high concentrations, carbenicillin, ticarcillin, piperacillin, and mezlocillin have good activity against gram-negative enterics and most anaerobes; however, they are not completely resistant to beta-lactamase.
- Cephalosporins
- The B fragilis group, Prevotella species, and Porphyromonas species are resistant to first-generation cephalosporins by virtue of cephalosporinase production.
- Cefoxitin is the most effective cephalosporin against the B fragilis group, although 5-15% may be resistant. Cefoxitin is inactive against most clostridial organisms, except Clostridium perfringens. Other second-generation cephalosporins, such as cefotetan and cefmetazole, have a longer half-life than cefoxitin and are as effective as cefoxitin against B fragilis; however, they are less efficacious against other members of the B fragilis group.
- Carbapenems: These agents, including imipenem, meropenem, and ertapenem have excellent activity against a broad spectrum of aerobic and anaerobic bacteria.
- Chloramphenicol: This agent shows excellent in vitro activity against most anaerobic bacteria, and resistance is rare; however, the development of less toxic newer agents has limited their use.
- Clindamycin: This antimicrobial is effective against anaerobes and has good activity against aerobic gram-positive cocci. Resistance of the B fragilis group is 5-25%. Antibiotic-associated colitis due to Clostridium difficile, although associated with most antimicrobials, was first described following clindamycin therapy.
- Metronidazole: It has excellent activity against anaerobes, including AGNB; however, this efficacy is limited to anaerobes. Microaerophilic streptococci, P acnes, and Actinomyces species are often resistant; therefore; adding an antimicrobial that is effective against these organisms (eg, penicillin) is often necessary.
- Tigecycline: This glycylcycline has effective in vitro activity against both gram-positive and gram-negative anaerobes, as well as against gram-positive aerobic strains such as methicillin-resistant staphylococci, streptococci, and enterococci. Tigecycline was recently approved by the FDA for the treatment of complicated skin and skin-structure infections and complicated intra-abdominal infections.
- Quinolones: Trovafloxacin, moxifloxacin, and gatifloxacin yield low minimum inhibitory concentrations (MICs) against most groups of anaerobes. Moxifloxacin was recently approved by the FDA for the treatment of complicated skin and skin-structure infections and complicated intra-abdominal infections. The use of the quinolones is restricted in growing children and pregnancy because of their possible adverse effects on the cartilage.
Surgical Care: - In most cases, surgical therapy is of critical importance. Surgical therapy includes draining abscesses, debriding necrotic tissues, decompressing closed-space infections, and relieving obstructions.
- When surgical drainage is not used, the infection may persist and serious complications may develop.
|   |
MEDICATION
| Section 6 of 9  |
|
Clinical judgment, personal experience, safety, and patient compliance should direct the physician in the choice of the appropriate antimicrobial agents. When choosing antimicrobials for the therapy of mixed infections, their aerobic and anaerobic antibacterial spectrum and their availability in oral or parenteral form should be considered. Some antimicrobials have a limited range of activity. For example, metronidazole is active only against anaerobes and therefore cannot be administered as a single agent for the therapy of mixed infections. Others (ie, carbapenems) have wide spectra of activity against aerobes and anaerobes.
Aside from susceptibility patterns, other factors influencing the choice of antimicrobial therapy include the pharmacologic characteristics of the various drugs, their toxicity, their effect on the normal florae, and their bactericidal activity. Although identification of the infecting organisms and their antimicrobial susceptibility may be needed for selection of optimal therapy, the clinical setting and Gram stain preparation of the specimen may indicate the types of anaerobes present in the infection and the nature of the infectious process.
Although the duration of therapy for anaerobic infections is generally longer than for aerobes and facultative infections, the duration of treatment must be individualized, depending on the response. In some cases, treatment may require 6-8 weeks, but therapy may be shortened with proper surgical drainage. An anti–gram-negative enteric agent is generally added to treat Enterobacteriaceae when treating intra-abdominal infections.
The available parenteral antimicrobials for most infections are clindamycin, metronidazole, chloramphenicol, cefoxitin, a penicillin (ie, ticarcillin, ampicillin, piperacillin) and a beta-lactamase inhibitor (ie, clavulanic acid, sulbactam, tazobactam), and a carbapenem (ie, imipenem, meropenem, ertapenem).
An agent effective against gram-negative enteric bacilli (ie, aminoglycoside) or an antipseudomonal cephalosporin (ie, cefepime) is generally added to clindamycin, metronidazole, and, occasionally, cefoxitin when treating intra-abdominal infections to provide coverage for these bacteria.
Penicillin can be added to metronidazole in the therapy of intracranial, pulmonary, or dental infections to cover microaerophilic streptococci and Actinomyces species.
A macrolide (ie, erythromycin) is added to metronidazole for upper respiratory tract infections to treat Staphylococcus aureus and aerobic streptococci.
Penicillin is added to clindamycin to supplement its coverage against Peptostreptococcus species and other gram-positive anaerobic organisms.
Penicillin is still the drug of choice for bacteremia caused by non–beta-lactamase producers. However, other agents should be used for the therapy of bacteremia caused by beta-lactamase producers.
For Chlamydia and Mycoplasma species, doxycycline is added to most regimens when treating pelvic infections.
Oral therapy is often substituted for parenteral therapy. The agents available for oral therapy are clindamycin, amoxicillin and clavulanate, and metronidazole.
Drug Category: Antimicrobials -- Empiric antimicrobial therapy must cover all likely pathogens in the context of this clinical setting. Drug Name
| Penicillin G (Pfizerpen) -- Interferes with synthesis of cell wall mucopeptide during active multiplication, resulting in bactericidal activity against susceptible microorganisms (beta-lactam). |
|---|
| Adult Dose | 10-28 million U/d IV |
|---|
| Pediatric Dose | 50,000-100,000 U/d IV |
|---|
| Contraindications | Documented hypersensitivity |
|---|
| Interactions | Probenecid can increase effects; coadministration of tetracyclines can decrease effects |
|---|
| Pregnancy |
A - Safe in pregnancy
|
|---|
| Precautions | Caution in impaired renal function |
|---|
Drug Name
| Cefoxitin (Mefoxin) -- Second-generation cephalosporin indicated for gram-positive cocci and gram-negative rod infections. Infections caused by cephalosporin- or penicillin-resistant gram-negative bacteria may respond. |
|---|
| Adult Dose | 1-2 g IV q6h |
|---|
| Pediatric Dose | 40 mg/kg/d IV q6h |
|---|
| Contraindications | Documented hypersensitivity |
|---|
| Interactions | Probenecid may increase effects; coadministration with aminoglycosides or furosemide may increase nephrotoxicity (closely monitor renal function) |
|---|
| Pregnancy |
B - Usually safe but benefits must outweigh the risks.
|
|---|
| Precautions | Bacterial or fungal overgrowth of nonsusceptible organisms may occur with prolonged use or repeated treatment; caution in patients with previously diagnosed colitis |
|---|
Drug Name
| Cefotetan (Cefotan) -- Second-generation cephalosporin indicated for infections caused by susceptible gram-positive cocci and gram-negative rods. Dosage and route of administration depend on condition of patient, severity of infection, and susceptibility of causative organism. |
|---|
| Adult Dose | 1-2 g IV q12h; not to exceed 4 g/d |
|---|
| Pediatric Dose | 20-40 mg/kg/dose IV q12h for 5-10 d |
|---|
| Contraindications | Documented hypersensitivity |
|---|
| Interactions | Consumption of alcohol within 72 h of administration may produce disulfiramlike reactions; may increase hypoprothrombinemic effects of anticoagulants; coadministration with potent diuretics (eg, loop diuretics) or aminoglycosides may increase nephrotoxicity |
|---|
| Pregnancy |
B - Usually safe but benefits must outweigh the risks.
|
|---|
| Precautions | Reduce dosage by half if CrCl <10-30 mL/min and by one fourth if CrCl <10 mL/min; bacterial or fungal overgrowth of nonsusceptible organisms may occur with prolonged or repeated therapy |
|---|
Drug Name
| Clindamycin (Cleocin) -- Lincosamide for treatment of serious skin and soft tissue staphylococcal infections. Also effective against aerobic and anaerobic streptococci (except enterococci). Inhibits bacterial growth, possibly by blocking dissociation of peptidyl tRNA from ribosomes causing RNA-dependent protein synthesis to arrest. |
|---|
| Adult Dose | 150-450 mg PO q6h 450-900 mg IV q8h |
|---|
| Pediatric Dose | 20-30 mg/kg/d PO divided q6h
25-40 mg/kg/d PO divided q6-8h| Contraindications | Documented hypersensitivity; regional enteritis; ulcerative colitis; hepatic impairment; antibiotic-associated colitis |
|---|
| Interactions | Increases duration of neuromuscular blockade induced by tubocurarine and pancuronium; erythromycin may antagonize effects; antidiarrheals may delay absorption |
|---|
| Pregnancy |
C - Safety for use during pregnancy has not been established.
|
|---|
| Precautions | Adjust dose in severe hepatic dysfunction; no adjustment necessary in renal insufficiency; associated with severe and possibly fatal colitis |
|---|
|
|---|
Drug Name
| Amoxicillin and clavulanate (Augmentin) -- Amoxicillin inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins. Addition of clavulanate inhibits beta-lactamase–producing bacteria.
Good alternative antibiotic for patients allergic to or intolerant to macrolides. Usually is well tolerated and provides good coverage for most infectious agents. Not effective against Mycoplasma and Legionella species. Half-life of oral dosage form is 1-1.3 h. Has good tissue penetration but does not enter cerebrospinal fluid.
For children >3 mo, base dosing protocol on amoxicillin content. Because of different ratios of amoxicillin to clavulanic acid in 250-mg tab (250/125) vs 250-mg chewable tab (250/62.5), do not use 250-mg tab until child weighs >40 kg.| Adult Dose | 500 mg PO q8h or 875 mg PO q12h |
|---|
| Pediatric Dose | <3 months: 125 mg/5 mL PO susp based on amoxicillin; 30 mg/kg/d divided bid
>3 months: If using 200 mg/5 mL or 400 mg/5 mL susp, 45 mg/kg/d PO q12h; if using 125 mg/5 mL or 250 mg/5 mL susp, 40 mg/kg/d PO q8h
>40 kg: Administer as in adults| Contraindications | Documented hypersensitivity |
|---|
| Interactions | Coadministration with warfarin or heparin increases risk of bleeding |
|---|
| Pregnancy |
B - Usually safe but benefits must outweigh the risks.
|
|---|
| Precautions | Administer for a minimum of 10 d to eliminate organism and to prevent sequelae (eg, endocarditis, rheumatic fever); following treatment, perform cultures to confirm eradication of streptococci |
|---|
|
|---|
|
|---|
Drug Name
| Ticarcillin and clavulanate potassium (Timentin) -- Inhibits biosynthesis of cell wall mucopeptide and is effective during stage of active growth. Antipseudomonal penicillin plus beta-lactamase inhibitor that provides coverage against most gram-positive organisms, most gram-negative organisms, and most anaerobes. Contains 4.7-5.0 mEq of Na+/g. |
|---|
| Adult Dose | 3.1 g IV q4-6h |
|---|
| Pediatric Dose | 200-300 mg/kg/d IV q4-6h |
|---|
| Contraindications | Documented hypersensitivity; severe pneumonia, bacteremia, pericarditis, emphysema, meningitis, and purulent or septic arthritis should not be treated with oral penicillin during acute stage |
|---|
| Interactions | Tetracyclines may decrease effects; high concentrations may physically inactivate aminoglycosides if administered in same IV line; effects are synergistic when administered concurrently with aminoglycosides; probenecid may increase levels |
|---|
| Pregnancy |
B - Usually safe but benefits must outweigh the risks.
|
|---|
| Precautions | Perform CBC counts prior to initiation of therapy and at least weekly during therapy; monitor for liver function abnormalities by measuring AST and ALT during therapy; exercise caution in patients with hepatic insufficiencies; perform urinalysis and BUN/creatinine determinations during therapy, and adjust dose if values become elevated; monitor blood levels to avoid possible neurotoxic reactions |
|---|
Drug Name
| Chloramphenicol (Chloromycetin) -- Binds to 50S bacterial ribosomal subunits and inhibits bacterial growth by inhibiting protein synthesis. Effective against gram-negative and gram-positive bacteria. |
|---|
| Adult Dose | 0.25-1 g IV q6h; not to exceed 4 g/d |
|---|
| Pediatric Dose | 80-100 mg/kg/d IV |
|---|
| Contraindications | Documented hypersensitivity |
|---|
| Interactions | Concurrently with barbiturates, chloramphenicol serum levels may decrease while barbiturate levels may increase, causing toxicity; manifestations of hypoglycemia may occur with sulfonylureas; rifampin may reduce serum levels, presumably through hepatic enzyme induction; may increase effects of anticoagulants; may increase serum hydantoin levels, possibly resulting in toxicity; levels may be increased or decreased |
|---|
| Pregnancy |
C - Safety for use during pregnancy has not been established.
|
|---|
| Precautions | Use only for indicated infections or as prophylaxis for bacterial infections; serious and fatal blood dyscrasias (eg, aplastic anemia, hypoplastic anemia, thrombocytopenia, granulocytopenia) can occur; evaluate baseline, and perform periodic blood studies approximately every 2 d while in therapy; discontinue upon appearance of reticulocytopenia, leukopenia, thrombocytopenia, or anemia or upon findings attributable to chloramphenicol; adjust dose in liver or kidney dysfunction; caution in pregnancy at term or during labor because of potential toxic effects on fetus (gray syndrome) |
|---|
Drug Name
| Imipenem and cilastatin (Primaxin) -- Carbapenem used for treatment of multiple organism infections in which other agents do not have wide-spectrum therapeutic activity or are contraindicated because of potential toxicity. |
|---|
| Adult Dose | 500-750 mg IV q6h; not to exceed 3 g/d IV |
|---|
| Pediatric Dose | <12 years: Not established; 15-25 mg/kg/d IV suggested
>12 years: 15-25 mg/kg/d IV| Contraindications | Documented hypersensitivity |
|---|
| Interactions | Coadministration with cyclosporine may increase CNS adverse effects of both agents; coadministration with ganciclovir may result in generalized seizures |
|---|
| Pregnancy |
C - Safety for use during pregnancy has not been established.
|
|---|
| Precautions | Adjust dose in impaired renal function; high doses can cause seizures and renal failure, especially in elderly persons and in those with prior seizure disorder; adverse effects include phlebitis, transitory hypotension, hepatotoxicity, vomiting, and diarrhea |
|---|
|
|---|
Drug Name
| Meropenem (Merrem) -- Broad-spectrum carbapenem antibiotic that inhibits cell wall synthesis and has bactericidal activity. Effective against most gram-positive and gram-negative bacteria. Has slightly increased activity against gram-negative bacteria and slightly decreased activity against staphylococci and streptococci compared with imipenem. Also less likely to cause seizures compared with imipenem. |
|---|
| Adult Dose | 1 g IV q8h |
|---|
| Pediatric Dose | 40 mg/kg IV q8h |
|---|
| Contraindications | Documented hypersensitivity |
|---|
| Interactions | Probenecid may inhibit renal excretion, increasing levels |
|---|
| Pregnancy |
C - Safety for use during pregnancy has not been established.
|
|---|
| Precautions | Pseudomembranous colitis and thrombocytopenia may occur, requiring immediate discontinuation |
|---|
Drug Name
| Metronidazole (Flagyl) -- Imidazole ring-based antibiotic active against various anaerobic bacteria and protozoa. Used in combination with other antimicrobial agents (except for C difficile enterocolitis). |
|---|
| Adult Dose | 375-750 mg IV q8h |
|---|
| Pediatric Dose | 30 mg/kg/d IV q6h |
|---|
| Contraindications | Documented hypersensitivity |
|---|
| Interactions | Cimetidine may increase toxicity; may increase effects of anticoagulants; may increase toxicity of lithium and phenytoin; disulfiramlike reaction may occur with orally ingested ethanol |
|---|
| Pregnancy |
B - Usually safe but benefits must outweigh the risks.
|
|---|
| Precautions | Pregnancy category X in first trimester; has shown mutagenicity in Ames test; tumorigenicity shown in animals but not in humans; adjust dose in hepatic disease; monitor for seizures and development of peripheral neuropathy |
|---|
Drug Name
| Ertapenem (Invanz) -- Bactericidal activity results from inhibition of cell wall synthesis and is mediated through ertapenem binding to penicillin-binding proteins. Stable against hydrolysis by a variety of beta-lactamases, including penicillinases, cephalosporinases, and extended-spectrum beta-lactamases. Hydrolyzed by metallo-beta-lactamases. |
|---|
| Adult Dose | 1 g/d for 14 d if given IV and for 7 d if given IM; infuse over 30 min if given IV |
|---|
| Pediatric Dose | Not established |
|---|
| Contraindications | Documented hypersensitivity |
|---|
| Interactions | Probenecid may reduce renal clearance and increase half-life but benefit is minimal and does not justify coadministration |
|---|
| Pregnancy |
B - Usually safe but benefits must outweigh the risks.
|
|---|
| Precautions | Pseudomembranous colitis may occur; seizures and adverse CNS reactions may occur; when using with lidocaine to administer IM, avoid inadvertent injection into blood vessel |
|---|
Drug Name
| Moxifloxacin (Avelox) -- Inhibits the A subunits of DNA gyrase, resulting in inhibition of bacterial DNA replication and transcription. |
|---|
| Adult Dose | 400 mg PO/IV qd |
|---|
| Pediatric Dose | <18 years: Not recommended
>18 years: Administer as in adults| Contraindications | Documented hypersensitivity; known QT prolongation, concurrent administration of drugs that cause QT prolongation |
|---|
| Interactions | Antacids and electrolyte supplements reduce absorption; loop diuretics, probenecid, and cimetidine increase serum levels; NSAIDs enhance CNS stimulating effect
May increase toxicity of theophylline, caffeine, cyclosporine, and digoxin (monitor digoxin levels); may increase effects of anticoagulants (monitor PT); ferrous sulfate decreases bioavailability (administer moxifloxacin 4 h prior or 8 h following ferrous sulfate); coadministration with drugs that prolong QTc interval (quinidine, procainamide, amiodarone, sotalol, erythromycin, tricyclic antidepressants) increase risk of life-threatening arrhythmia| Pregnancy |
D - Unsafe in pregnancy
|
|---|
| Precautions | In prolonged therapy, periodically evaluate organ system functions (eg, renal, hepatic, hematopoietic); superinfections may occur with prolonged or repeated antibiotic therapy; fluoroquinolones have induced seizures in CNS disorders and caused tendinitis or tendon rupture |
|---|
|
|---|
|
|---|
Drug Name
| Tigecycline (Tygacil) -- A glycylcycline antibiotic that is structurally similar to tetracycline antibiotics. Inhibits bacterial protein translation by binding to 30S ribosomal subunit and blocks entry of amino-acyl tRNA molecules in ribosome A site. Indicated for complicated skin and skin structure infections caused by E coli, E faecalis (vancomycin-susceptible isolates only), S aureus (methicillin-susceptible and -resistant isolates), S agalactiae, S anginosus group (includes S anginosus, S intermedius, and S constellatus), S pyogenes, and B fragilis. |
|---|
| Adult Dose | Infuse each dose over 30-60 min
100 mg IV once, then 50 mg IV q12h
Severe hepatic impairment (ie, Child Pugh class C): 100 mg IV once, then 25 mg IV q12h| Pediatric Dose | <18 years: Not established
>18 years: Administer as in adults| Contraindications | Documented hypersensitivity |
|---|
| Interactions | Coadministration decreases warfarin clearance and increases warfarin Cmax and AUC (monitor aPTT and INR); coadministration of antibiotics with oral contraceptives may decrease contraceptive effect |
|---|
| Pregnancy |
D - Unsafe in pregnancy
|
|---|
| Precautions | Caution in severe hepatic impairment (reduce dose); may adversely effect tooth development; may permit clostridia overgrowth, resulting in antibiotic-associated colitis; may have adverse effects similar to tetracyclines (eg, photosensitivity, pseudotumor cerebri, pancreatitis, antianabolic action) |
|---|
|
|---|
|
|---|
|   |
FOLLOW-UP
| Section 7 of 9  |
|
Deterrence/Prevention:
- Where AGNB and other anaerobes predominate, early and aggressive treatment of acute infection can prevent chronic infections.
- When the risk of anaerobic infections (eg, intra-abdominal and wound infection following surgery) is high, proper antimicrobial prophylaxis may reduce the risk.
- Preventing oral florae aspiration by improving neurologic status, suctioning oral secretions, improving oral hygiene, and maintaining lower stomach pH can reduce the risk of aspiration pneumonia and its complications.
- Irrigation and debridement of wounds and necrotic tissue, drainage of pus, and improvement of the blood supply help prevent skin and soft tissue infections.
Patient Education:
|   |
MISCELLANEOUS
| Section 8 of 9  |
|
Medical/Legal Pitfalls:
- Failure to promptly and properly institute the following 3 principles:
- Neutralization of toxins produced by anaerobes
- Prevention of local bacterial proliferation by changing the environment
- Limitation of bacterial spread
|   |
BIBLIOGRAPHY
| Section 9 of 9 |
|
-
Aldridge KE, Ashcraft D, Cambre K, et al: Multicenter survey of the changing in vitro antimicrobial susceptibilities of clinical isolates of Bacteroides fragilis group, Prevotella, Fusobacterium, Porphyromonas, and Peptostreptococcus species. Antimicrob Agents Chemother 2001 Apr; 45(4): 1238-43[Medline].
-
Bartlett JG: Anaerobic bacterial infections of the lung and pleural space. Clin Infect Dis 1993 Jun; 16 Suppl 4: S248-55[Medline].
-
Blairon L, De Gheldre Y, Delaere B, et al: A 62-month retrospective epidemiological survey of anaerobic bacteraemia in a university hospital. Clin Microbiol Infect 2006 Jun; 12(6): 527-32[Medline].
-
Bohnen JM: Antibiotic therapy for abdominal infection. World J Surg 1998 Feb; 22(2): 152-7[Medline].
-
Brook I: Indigenous microbial flora of humans. In: Surgical Infectious Diseases. 3rd ed. Norwalk, Conn: Appleton & Lange; 1995: 37.
-
Brook I: Pediatric anaerobic infection: Diagnosis and Management. Revised and Expanded. 3rd ed. New York, NY: Marcell Dekker; 2002.
-
Brook I: Enhancement of growth of aerobic and facultative bacteria in mixed infections with Bacteroides species. Infect Immun 1985 Dec; 50(3): 929-31[Medline].
-
Brook I: Prevalence of beta-lactamase-producing bacteria in chronic suppurative otitis media. Am J Dis Child 1985 Mar; 139(3): 280-3[Medline].
-
Brook I, Thompson DH, Frazier EH: Microbiology and management of chronic maxillary sinusitis. Arch Otolaryngol Head Neck Surg 1994 Dec; 120(12): 1317-20[Medline].
-
Brook I: The role of beta-lactamase-producing bacteria in the persistence of streptococcal tonsillar infection. Rev Infect Dis 1984 Sep-Oct; 6(5): 601-7[Medline].
-
Brook I, Frazier EH: Clinical and microbiological features of necrotizing fasciitis. J Clin Microbiol 1995 Sep; 33(9): 2382-7[Medline].
-
Brook I: Anaerobic bacterial bacteremia: 12-year experience in two military hospitals. J Infect Dis 1989 Dec; 160(6): 1071-5[Medline].
-
Doan TL, Fung HB, Mehta D, Riska PF: Tigecycline: a glycylcycline antimicrobial agent. Clin Ther 2006 Aug; 28(8): 1079-106[Medline].
-
Durmaz B, Dalgalar M, Durmaz R: Prevalence of Enterotoxigenic Bacteroides fragilis in patients with diarrhea: A controlled study. Anaerobe 2005 Dec; 11(6): 318-21[Medline].
-
Finegold SM: Anaerobic Bacteria in Human Disease. Orlando, Fla: Academic Press; 1977.
-
Goldstein EJ: Current concepts on animal bites: bacteriology and therapy. Curr Clin Top Infect Dis 1999; 19: 99-111[Medline].
-
Jousime-Somers H, Summanen P, Citron DM: Wadsworth-KTL Anaerobic Bacteriology Manual. 6th ed. Belmont, Calif: Star Publishing; 2002.
-
Lewis RP, Sutter VL, Finegold SM: Bone infections involving anaerobic bacteria. Medicine (Baltimore) 1978 Jul; 57(4): 279-305[Medline].
-
Nakano V, Padilla G, do Valle Marques M, Avila-Campos MJ: Plasmid-related beta-lactamase production in Bacteroides fragilis strains. Res Microbiol 2004 Dec; 155(10): 843-6[Medline].
-
Nord CE: The role of anaerobic bacteria in recurrent episodes of sinusitis and tonsillitis. Clin Infect Dis 1995 Jun; 20(6): 1512-24[Medline].
-
Wexler HM, Finegold SM: Current susceptibility patterns of anaerobic bacteria. Yonsei Med J 1998 Dec; 39(6): 495-501[Medline].
Bacteroides Infection excerpt |